Skip to content

Knowledge Services

Everything you need to know about Federal policies impacting your work.


Real-time “what-it-means-to-you” analysis of key Federal policies impacting your goals


Forward-looking insight into the policy trajectory for your priority issues


In-depth, actionable breakdowns of all relevant regulations and guidance


Concise summaries of impactful policy-driving events, including congressional hearings, agency forums, and MedPAC and MACPAC sessions


Detailed briefs of major health care bills, with assessments of their probability of passage and tracking of relevant legislation


Monitoring of all relevant Federal grant, advisory board nomination, and demonstration opportunities


Our proprietary Issue Brief series, breaking down the status of the hottest topics in health


A Weekly newsletter framing the upcoming week and recapping recent developments of interest

Policy Hub

Unlimited subscriptions to Policy Hub, our searchable knowledge database and daily e-digest


Ways and Means Committee Examines H.R. 3, the Lower Drug Costs Now Act, and Education and Labor Committee Favorably Reports AINS to H.R. 3

The House Ways and Means Committee convened a hearing to discuss H.R. 3, the Lower Drug Costs Now Act (summary). The Ways and Means Committee is the third House Committee to examine the bill. Witnesses testified about the difficulties both privately insured beneficiaries and Medicare beneficiaries face in affording their medications and how H.R. 3 savings could be reinvested into… (Slifer, 10/17/19) #Insurance Reform, #Medicare Part D, #Prescription Drugs

Subcommittee Examines E-Cigarettes and Youth Tobacco Epidemic

The House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies convened a hearing to examine the Centers for Disease Control and Prevention’s (CDC) ongoing investigation of lung injury associated with e-cigarette use, discuss the youth tobacco epidemic, and identify public policy remedies. Overall, members from both parties agreed that efforts should be made to prevent children… (Llamas, 10/16/19) #Food and Drug Administration, #Pediatrics, #Public Health

Initial Cost Estimates of H.R. 3; Price Negotiation, Inflation Rebates Analyzed

The Congressional Budget Office (CBO) released a preliminary cost estimate of title I of the Lower Drug Costs Now Act of 2019 (H.R. 3) regarding price negotiation of certain prescription drugs in Medicare Part D. CBO estimates that enacting title I would reduce federal spending for Medicare by $345 billion over the 2023-2029 period. A summary follows below. Title I… (Llamas) #Insurance Reform, #Medicare Part D, #Prescription Drugs


Improving Health is Our Policy